 | | Vol. 12.28 – 20 July, 2021 |
| |
|
|
| Researchers characterized the cellular and developmental context of preleukemic initiation and leukemic progression using gene editing in human disomic and trisomic fetal hematopoietic cells and xenotransplantation.
[Science] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors performed single-cell transcriptome analysis of residual hematopoietic stem and progenitor cells and T cells to identify the molecular players from patients with aplastic anemia.
[Blood] |
|
|
|
| Mutant IDH2 (mIDH2) R140Q commonly had K413 acetylation, which negatively regulated mIDH2 activity in human acute myeloid leukemia (AML) cells by attenuating dimerization and blocking the binding of substrate and cofactor.
[Molecular Cell] |
|
|
|
| Scientists studied the function of GPX4 and ferroptosis in hematopoietic stem and progenitor cells in mice with Gpx4 deficiency in the hematopoietic system. HSCs and hematopoietic progenitor cells lacking Gpx4 accumulated lipid peroxidation and underwent ferroptosis in vitro.
[Cell Death & Disease] |
|
|
|
| Investigators established an acquired glucocorticoid-resistant leukemia cell model and found a long noncoding RNA, HOTAIRM1, was overexpressed in the resistant cells by transcriptional profiling, and was higher expressed in patients with poor prognosis.
[Cell Death & Disease] |
|
|
|
| To obtain insight into changes in translation induced by ribosomal protein S15 (RPS15) mutations in chronic lymphocytic leukemia (CLL) cells, researchers evaluated primary CLL cells from patients with wild-type or mutant RPS15 as well as MEC1 CLL cells transfected with mutant or wild-type RPS15.
[Blood Advances] |
|
|
|
| Scientists investigated the mechanism by which curcumin affected the resistance of acute myeloid leukemia to Adriamycin by regulating HOX transcript antisense RNA (HOTAIR) expression.
[Laboratory Investigation] |
|
|
|
| The authors analyzed the genomic architecture of CD138+ cells isolated from bone marrow aspirates from an unselected cohort of patients with extramedullary disease and intramedullary multiple myeloma and revealed an association of chromosome 1 abnormalities in bone marrow myeloma cells with extramedullary progression.
[Scientific Reports] |
|
|
|
| miRNA profiles were evaluated and eight miRNAs were found to be differentially expressed in patient-derived cell lines in comparison to controls. miR-181c was predicted to target myeloid cell leukemia (MCL)1, which was confirmed by transfection assays, resulting in significantly reduced MCL1 mRNA and decreased live cell numbers.
[Journal of Leukocyte Biology] |
| |
|
|
| In this Phase II study, patients received eight 28-day cycles of carfilzomib (K), lenalidomide (R), and dexamethasone (d). All patients proceeded to transplant after four cycles and received one year of lenalidomide maintenance. The eight cycles of KRd produced fast and deep responses in transplant-eligible patients with newly diagnosed multiple myeloma.
[Blood] |
|
|
|
| Investigators retrospectively compared the outcomes of 20 patients receiving Venetoclax + low-dose Cytarabine + Actinomycin D with 29 patients receiving FLAG-Ida as salvage therapy for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation.
[Bone Marrow Transplantation] |
|
|
|
| Untreated older acute myeloid leukemia (AML) patients were randomized to cytarabine and daunorubicin followed by cytarabine consolidation with or without G3139. Addition of G3139 to chemotherapy failed to improve outcomes of older AML patients.
[Blood Advances] |
|
|
|
|
| The authors delineate the role of the endothelium in severe complications after allogeneic hematopoietic stem cell transplantation and describe the current status of the search for biomarkers predicting endothelial complications, including markers of endothelial vulnerability and markers of endothelial injury.
[Bone Marrow Transplantation] |
|
|
|
| Scientists discuss the experimental evidence reported in recent years linking erythropoietin (Epo) and central nervous system function through investigations aimed at finding benefits in the treatment of neurodegenerative diseases and review the proposed mechanisms for novel derivatives which may improve the neuroprotective action of Epo.
[Journal of Neurochemistry] |
|
|
|
|
| LAVA Therapeutics NV announced dosing of the first patient in the company’s Phase I/IIa clinical trial of LAVA-051 in patients with relapsed and/or refractory chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.
[LAVA Therapeutics, NV] |
|
|
|
| GlycoMimetics, Inc. has announced that clinicians at University of California Davis Comprehensive Cancer Center initiated dosing of the first patient in a clinical study of uproleselan combined with venetoclax and azacitidine for the treatment of older or unfit patients with treatment-naïve acute myeloid leukemia.
[GlycoMimetics, Inc.] |
|
|
|
|
| September 20 – 23, 2021
Virtual |
|
|
|
|
|
| | Aarhus University – Aarhus, Denmark |
|
|
|
| | University of Wisconsin–Madison – Madison, Wisconsin, United States |
|
|
|
| | Karolinska Institutet – Flemingsberg, Sweden |
|
|
|
| | The Technical University of Munich – Munich, Germany |
|
|
|
| | The Westmead Institute for Medical Research – Sydney, Australia |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
